Introduction
Many components of signal transduction networks are now known to be able to localize to different cellular compartments, where they may exert rather diverse functions, often dictated by the interaction with compartment-specific partners. For example, p53's role as a transcriptional regulator in the nucleus has been recently joined by a direct proapoptotic function in the mitochondria, where p53 interacts with and activates Bak (reviewed in Murphy et al., 2004) . Moreover, the tumor suppressor p27KIP1, which is localized in the nucleus where it functions as a cyclin/cdk inhibitor, also acts as an oncoprotein in the cytoplasm, where it binds to and inhibits RhoA, thus modulating cell motility (Besson et al., 2004) .
While it is becoming more and more ordinary to discover that multitasking and 'multilocalizing' is a rather common feature of single signaling molecules, finding an entire signal transduction cascade completely replicated in two different subcellular compartments is certainly more surprising. Nevertheless, old anecdotic data and novel findings are now coming together in a quite unexpected picture, helping place in a very reasonable physiological context a number of findings gathered over the course of the last several years.
PTEN: a multifaceted tumor suppressor
The PTEN/MMAC1/TEP1 tumor suppressor gene (Li and Sun, 1997; Steck et al., 1997) is located on chromosome 10q23, a genomic region undergoing loss of heterozygosity (LOH) in many human cancers. Somatic deletions or mutations of this gene have been identified in a large fraction (12-60%) of tumors, placing PTEN among the most commonly mutated genes in human cancer (Ali et al., 1999) . Loss of PTEN is more often associated with advanced stage tumors, such as glioblastoma (Rasheed et al., 1999) , prostate cancer (Montironi et al., 2004) and melanoma (Wu et al., 2003) . However, there is one remarkable exception, represented by the endometrioid subtype of endometrial cancer (EEC). Loss of the 10q23 chromosomal region, where PTEN resides, is a common finding in primary EEC (Peiffer et al., 1995) . PTEN is mutated in about 37-51% of primary EECs (Tashiro et al., 1997; Risinger et al., 1998; Sun et al., 2001) . Strikingly, the analysis of endometrial hyperplasias, the precancerous lesions of the endometrium, has revealed that PTEN is already mutated in at least 20% of cases (Levine et al., 1998; Maxwell et al., 1998; Yoshinaga et al., 1998; Sun et al., 2001) . Thus, contrary to most other tumor types, loss of PTEN is a very early event in the multistep process leading to EEC.
PTEN encodes a phosphatase whose main in vivo substrate is phosphatidylinositol (3,4,5)-triphosphate (PIP3), the product of phosphatidylinositol-3 kinase (PI3K) activity (Maehama and Dixon, 1998) . The levels of PIP3 are very low in quiescent cells, but rapidly increase upon stimulation by growth factors, through activation of PI3K. Accumulation of PIP3 at the plasma membrane allows recruitment of proteins containing a pleckstrin homology (PH) domain, which binds PIP3. Among these proteins are the three AKT serine/ threonine kinase family members. Activated AKT, in turn, phosphorylates an ever-growing list of target proteins, thus regulating key processes such as proliferation, survival, cell size and mRNA translation (Bellacosa et al., 2005) . These various processes are discussed in detail in several reviews found in this issue of Oncogene Reviews (see e.g., Plas and Thompson, Ruggero and Sonenberg, and Greer and Brunet).
The structural characteristics of PTEN do not rule out that it may exert phosphatase activity against particularly acidic protein substrates (Lee et al., 1999) . Actually, it had been proposed that PTEN might counteract cell migration, invasion and focal adhesion formation by acting as a negative regulatory molecule in the integrin-mediated signaling cascade at focal adhesions, by directly inactivating FAK (Tamura et al., 1998 (Tamura et al., 1999a, b) . This putative protein-specific activity of PTEN has been invoked to be also responsible for other PTEN-mediated effects. For example, it has been proposed that PTEN would induce cell cycle arrest at least in part by reducing cyclin D1 levels through its protein phosphatase activity (Weng et al., 2001) . Despite many efforts, however, these findings still lack conclusive validation. Nevertheless, they suggest the existence of lipid phosphatase-independent PTEN cellular functions that are not sufficient to suppress tumorigenesis (the lipid phosphatase activity is in fact essential for tumor suppression), but may instead contribute to different aspects of tumor progression.
Nearly all aspects of PTEN tumor suppressive activity, as well as the pathways that are altered upon loss of PTEN, have been already exhaustively discussed in other reviews (Di Cristofano and Pandolfi, 2000; Parsons, 2004; Sansal and Sellers, 2004) . Most current efforts are aimed at dissecting the mechanisms controlling PTEN. The expression and activity of PTEN appear to be regulated through several mechanisms, including transcriptional modulation (Stambolic et al., 2001; Kim et al., 2004; Tell et al., 2004) , protein-protein interactions (Wu et al., 2000a, b) , redox state (Kwon et al., 2004) and phosphorylation (Vazquez et al., 2000; Tolkacheva et al., 2001; Torres and Pulido, 2001; Okahara et al., 2004; Valiente et al., 2005) . Phosphorylation of Ser380, Thr382 and Thr383, which are located in the last 50 amino acids of the protein (the so-called 'tail'), has been specifically associated with an increased stability and a decreased catalytic activity of PTEN. More recently, a novel twist has been added to this story. It appears that the small GTPase RhoA and its effector Rock can interact with PTEN and phosphorylate a different series of threonines and serines, located in the C2 domain, thus enhancing PTEN activity (Li et al., 2005) .
Nuclear PTEN: from artifact to fact
The structural characteristics of PTEN, namely the presence of a lipid-binding domain and the absence of obvious nuclear import/export signals, as well as the discovery of its role as a modulator of the PI3K/AKT pathway, led to the general understanding that PTEN localizes to the cytoplasm. In addition, the first papers that analysed PTEN intracellular localization, utilizing either overexpression systems (Furnari et al., 1997) or tumor cell lines (Whang et al., 1998) , found PTEN exclusively in the cytoplasm, thus strengthening the notion of a strictly cytoplasmic localization for this protein. As a consequence, the first papers describing the presence of PTEN in the nuclear compartment of normal primary neurons and endothelial cells (Sano et al., 1999) , as well as in the myoepithelial cells of normal breast ducts (Perren et al., 1999) , skated over this unexpected finding. At the same time, the initial attempts at proposing that PTEN might indeed move to and from the nucleus received a rather skeptical welcome, with the general agreement that the immunohistochemical data behind this hypothesis were very likely the result of an artifact.
However, with the increasing availability of different commercial antibodies, the reports of PTEN localization in the nucleus multiplied, and an interesting correlation between nuclear staining, cell proliferation/ differentiation and transformation began to take shape. Nuclear PTEN is in fact usually found in primary normal cells, rather than in tumor cell lines, and its presence is inversely correlated with cell proliferation and directly correlated with cell differentiation. For example, both pancreatic islet cells and normal melanocytes (Whiteman et al., 2002) express PTEN predominantly in the nucleus. Conversely, exocrine pancreatic tumors and melanomas show a dramatic reduction in nuclear staining and a corresponding increase in cytoplasmic localization, and in the latter case the loss of nuclear staining is associated with a higher mitotic index, thus suggesting that loss of nuclear PTEN is directly correlated with neoplastic transformation. The change in PTEN subcellular distribution during tumorigenesis is even more striking in the thyroid: while normal follicular cells are uniformly characterized by a stronger staining in the nucleus than in the cytoplasm, the nuclear staining intensity progressively diminishes during progression from normal to follicular adenoma to carcinoma and precedes the reduction in cytoplasmic staining that characterizes more advanced thyroid tumors (Gimm et al., 2000) . In normal colon epithelial cells, nuclear PTEN appears to be somewhat less prominent than cytoplasmic PTEN. However, almost 80% of colorectal cancer samples analysed by Zhou et al. (2002) showed partial or total loss of nuclear PTEN while less than 30% had loss of cytoplasmic staining. Nuclear PTEN staining is not found in all cell types as it appears that Schwann cells show only cytoplasmic staining . Finally, Pten has been found in the nucleus of neurons from several different areas of the mouse brain (Lachyankar et al., 2000) and of primary vascular smooth cells from the pig aorta (De´le´ris et al., 2003) .
The nuclear localization of PTEN is a dynamic process PTEN does not seem to be a stationary resident of the nucleus. Several reports have started shedding light on a very dynamic picture in which PTEN subcellular localization is dependent on ongoing differentiation processes, cell cycle status and hormonal stimulation.
Pten is not expressed in proliferating rat pheochromocytoma PC12 cells, or in primary CNS stem cells from the mouse subventricular zone (SVZ). However, NGFor BDNF-dependent neuronal differentiation of these in vitro models strongly induces Pten expression, first in a speckled pattern in the nucleus only, then in a more diffuse pattern in both the nucleus and the cytoplasm (Lachyankar et al., 2000) , suggesting that nuclear Pten may control some aspect of neuronal differentiation. However, antisense-mediated Pten depletion in this model does not affect the initial differentiation steps, but rather the survival of the nascent neurons.
The urgent need for additional well-controlled and indepth studies is underlined by the rather different results obtained when analysing in vitro the correlation between nuclear PTEN and cell cycle. De´le´ris et al. (2003) utilized primary vascular smooth cells from the pig aorta, arrested in G 0 by serum starvation and allowed to re-enter cell cycle by adding serum, and found that nuclear levels of Pten increased during progression through G 1 to peak in S-phase and then decreased in G 2 . Conversely, similar experiments in MCF-7 cells, synchronized by hydroxyurea treatment and then released into cell cycle, resulted in highest levels of nuclear PTEN in the G 1 -phase and lowest in the S-phase (Ginn-Pease and Eng, 2003). Despite differences that may be due to the cell systems used, endogenous vs overexpressed PTEN, or other experimental conditions, it appears that nuclear localization of PTEN is a very dynamic process, directly linked to cellular proliferation.
The picture becomes even more complex when analysed in vivo in a hormone-sensitive tissue. Endometrial expression of PTEN, in fact, appears to be extremely dynamic and to change according to the cell type examined. In the stroma, PTEN is highly expressed, more abundantly in the nucleus than in the cytoplasm, throughout the menstrual cycle, with a peak in the late secretory phase, when the cells undergo decidualization Guzeloglu-Kayisli et al., 2003) . This increase in PTEN expression might be related to the differentiation process that takes place in the stromal cells during decidualization, similar to what has been described for the neuronal differentiation of PC12 or SVZ stem cells. On the other hand, the endometrial epithelium expresses both nuclear and cytoplasmic PTEN during the early estrogen-driven proliferative phase, but PTEN levels rapidly decline once the progesterone-dominated secretory phase initiates, to completely disappear (nuclear PTEN first) between the mid-secretory and the menstrual phase . This expression pattern might reflect hormonedriven changes in protein stability, mRNA synthesis or both, which will require further investigation. It is interesting, though, that the levels of nuclear PTEN peak in the early proliferative phase, when cells are exposed to estrogen and growth factors and thus may need a strict control on the amount of proliferation allowed.
Interestingly, it appears that the PTEN molecules residing or migrating into the nucleus are phosphorylated on a cluster of serine and threonine residues in the carboxy-terminal tail, and that estrogen enhances this phosphorylation (Guzeloglu-Kayisli et al., 2003) . Phosphorylation of PTEN is a process regulating not only its stability and activity (Vazquez et al., 2000) , but also PTEN interaction with PDZ domain-containing proteins, which have been postulated to help recruit PTEN at the cell membrane (Tolkacheva et al., 2001 ). Thus, it is possible to speculate that tail phosphorylation releases PTEN from membrane-bound scaffolding proteins, and facilitates its shuttling into the nucleus.
One major obstacle to the hypothesis that PTEN migrates to the nucleus is the absence of any obvious nuclear import/export signal. This issue has been recently worked out by Chung et al. (2005) , who have used MCF-7 cells, expressing different PTEN mutants in an inducible manner, to show that nuclear localization depends on the presence of noncanonical nuclear localization signals (NLS). Mutation of any one of the putative sequences (identified based on homology with other noncanonical NLS) did not affect PTEN localization; however, two double mutants showed greatly impaired nuclear import, suggesting that these NLS function in pairs. Surprisingly, the carrier responsible for shuttling PTEN into the nucleus turns out not to be a member of the importin family, but rather major vault protein (MVP), a component of the ribonucleoprotein complexes known as vaults, which had previously been shown to interact with PTEN (Yu et al., 2002) . This seems to be the first example of a nuclear transport role for vaults, and thus these results will need to be extended to other cell types and confirmed with different approaches before claiming this as the only mechanism regulating PTEN nuclear import. Moreover, a still outstanding issue is the nuclear export mechanism. Again, no canonical export sequence has been identified in PTEN, but clearly a mechanism must be in place to ensure that PTEN exits the nucleus when not needed, as suggested by the experiments linking PTEN localization to the cell cycle dynamics.
PI3K signaling in the nucleus
The presence of PTEN in the nucleus should not come as a complete surprise: not only the existence of an independent nuclear phospholipid cycle has been demonstrated (Gillooly et al., 2000; Irvine, 2003; Martelli et al., 2003) , but in the past few years many proteins that participate in the plasma membraneinitiated phosphoinositide signaling cascade have been found to be localized also in the nucleus. PI3K is the first enzyme in this cascade, and is responsible for the generation of PIP3. All three known classes of PI3Ks have been found in the nucleus either as 'commuters', shuttling into the nucleus upon specific mitogenic (Kim, 1998; Metjian et al., 1999; Martelli et al., 2000) and differentiation (Neri et al., 1994 (Neri et al., , 1999a signals, or as 'permanent residents', constitutively co-localized with the nuclear speckles (Didichenko and Thelen, 2001) ; for a recent review see Neri et al., 2002) . In addition, estrogen, which is known to activate membrane-localized PI3K through direct interaction of ERa with the p85 subunit of PI3K (Simoncini et al., 2000) , has been recently shown to be also able to induce the generation of nuclear PIP3 through both classical ERa and the novel noncanonical estrogen receptor GPR30, a G proteincoupled receptor (Revankar et al., 2005) . A major outstanding issue is the mechanism of activation of nuclear PI3K: cytoplasmic PI3K is activated by receptor tyrosine kinases and by membrane-associated GTPases, but these proteins are not present in the nucleus. However, a number of recent reports have shown that, upon NGF stimulation, the nuclear GTPase, PIKE, can activate nuclear PI3K, thus playing a similar role to what Ras accomplishes at the cell membrane (Ye et al., 2000; Rong et al., 2003) . PIKE itself is activated by NGF through the nuclear translocation of PLCg1, which has been demonstrated to act as PIKE's guanine nucleotide exchange factor (GEF) (Ye et al., 2002) .
The generation of PIP3 at the plasma membrane results in the recruitment and activation of signaling proteins containing a PH domain, including PDK1 and AKT. The recent evidence that both these proteins are also present in the nucleus further strengthens the hypothesis that the entire PI3K-PDK1-AKT-PTEN axis is at work in this subcellular compartment.
Taken together, the available data suggest that PDK1 shuttles to the nucleus through a still undefined mechanism that is dependent on growth factor stimulation but does not require PDK1 catalytic activity nor an intact PH domain (Lim et al., 2003; Scheid et al., 2005) . Once in the nucleus, PDK1 is actively exported thanks to its nuclear export signal (NES) in a chromosome region maintenance 1 (CRM1)-dependent manner. PI3K activation results (through a still unidentified kinase) in the phosphorylation of PDK1 on Ser396, a residue that is adjacent to the NES and that, once phosphorylated, might alter the NES structure/function. Ser396 phosphorylation inhibits nuclear export but does not seem to be required for nuclear import. Thus, even though it is not yet clear whether the phosphorylation takes place at the membrane or once PDK1 is in the nucleus, the latter mechanism seems more plausible, being required to block PDK1 nuclear export.
There is a rather ample body of literature on the presence of activated AKT in the nucleus of tumor cells. Like PDK1, AKT has a CRM1-binding NES that promotes its nuclear export (Saji et al., 2005) ; however, the mechanism of nuclear entry is still unknown. The presence of nuclear, activated AKT has been detected in lung and breast primary tumors (Lee et al., 2002; Nicholson et al., 2003) . In the prostate, the extent of nuclear localization of activated AKT increases during the progression from normal tissue to low-grade PIN, high-grade PIN and tumor (Van de Sande et al., 2005) . Moreover, in the tumors, the extent of nuclear localization strongly correlates with the Gleason score. Interestingly, in primary follicular thyroid tumors, the localization of activated AKT is inversely correlated to the presence of PTEN in the nucleus: while nuclear PTEN levels diminish during the progression from normal tissue to adenoma to carcinoma, the levels of nuclear phosphorylated AKT increase (Vasko et al., 2004) .
Estrogen signaling increases AKT activation and localization in the nucleus of murine and human cardiomyocytes, and, interestingly, young women have higher levels of nuclear, active AKT than men or postmenopausal women (Camper-Kirby et al., 2001) . The effects of estrogen on the dynamics of activation and nuclear localization of AKT are again well described by the endometrial model system and reveal a strong inverse correlation between the presence of PTEN and active AKT in the nuclear compartment. The levels of active nuclear AKT in the glandular epithelium are low in the early proliferative phase, when the amount of nuclear PTEN is very high and selected cell populations undergo apoptosis (Kokawa et al., 1996) and then increase to peak in the late proliferative phase, when nuclear PTEN starts declining and proliferation is at its peak (Guzeloglu-Kayisli et al., 2003) . In the secretory phase, when cells do not proliferate and prepare for apoptosis, nuclear AKT levels are very low, as are those of PTEN. Stromal cells display a similar pattern, but the levels of phosphorylated, nuclear AKT drop to a minimum during decidualization, when nuclear PTEN is very high.
In primary hepatocytes, AKT is not activated and is localized to the cytoplasm. Upon insulin stimulation, AKT becomes phosphorylated at the cell membrane and then seems to move to the nuclear membrane. Conversely, in the transformed HepG2 cells, AKT is mostly phosphorylated and localized to the nucleus. Insulin stimulation further increases AKT activation and nuclear localization (Syed et al., 2002) . Immunofluorescence-based time-course experiments in 293T and REF-52 cells have shown that, upon growth factor stimulation, AKT is immediately recruited at the membrane, but 15 min later it is found mostly in the nucleus (Andjelkovic et al., 1997; Meier et al., 1997) . Thus, the common view is that AKT moves into the nucleus after being activated at the cell membrane.
However, it has been recently shown that phosphorylation of AKT is not required for nuclear translocation, even though activation of PI3K enhances AKT nuclear import and PI3K inhibitors prevent it (Saji et al., 2005) . These results are in agreement with other data showing that AKT nuclear localization in primary mouse endothelial cells depends on PI3K activation, but does not require AKT phosphorylation. Interestingly, at least in this cell system, AKT nuclear translocation needs the presence of RhoB (Adini et al., 2003) . In addition, IGF-I and PDGF stimulate an increase of nuclear, active AKT in MC3T3-E1 mouse calvaria fibroblasts with a kinetic that is slower than that of PI3K migration into the nucleus (Borgatti et al., 2000; Martelli et al., 2000) , suggesting that PI3K migration precedes accumulation of phosphorylated AKT in the nucleus. Finally, enforced expression of AKT in the nucleus of primary cardiomyocytes or in the heart of transgenic mice results in the accumulation of phosphorylated AKT, once again proving that AKT can undergo phosphorylation inside the nuclear compartment (Shiraishi et al., 2004) . Thus, as AKT phosphorylation is not required for its nuclear import, most nuclear AKT is phosphorylated (Adini et al., 2003) and all the proteins involved in AKT activation are on site, it is plausible that AKT activation takes place, at least in part, in the nucleus.
PTEN nuclear functions
The presence of PI3K, PDK1 and activated AKT in the nucleus clearly suggests that one of the functions of nuclear PTEN is the control of PIP3 levels and thus AKT activity. Indeed, the data obtained analysing the coordinated and cyclic variations of PTEN and AKT localization and activation in the endometrium support such hypothesis. It is not surprising that part of AKT activity takes place in this compartment, if we consider that several AKT substrates, such as Forkhead family members (including FKHR, FKHRL1, AFX, FOXO1a, -3a and 4), p21CIP, p27KIP, E2F, CREB, ERa and hTERT, are localized in the nucleus. The nuclear pathways regulated by AKT seem to be physiologically relevant, because an increase of AKT expression in the nucleus of cardiac cells is able to protect from staurosporine-or hypoxia-induced apoptosis in vitro and ischemia-reperfusion injury in vivo, without affecting cell size (as instead membrane-targeted myristoylated AKT does) or cell proliferation (Shiraishi et al., 2004) . However, besides the control of AKT, nuclear PTEN is likely to affect other pathways and proteins that have been shown to be activated by PIP3. NGFinduced differentiation of PC12 cells stimulates a very fast translocation of PI3K into the nucleus, its activation and the subsequent nuclear import of PKCx (Neri et al., 1999b) . PI3K activity appears to be strictly necessary for PKCx nuclear translocation and activation, thus uncovering a pathway that might be directly modulated by nuclear PTEN activity.
More recently, the same NGF-PC12 model has been used to demonstrate that the nucleolar protein NPM, involved in different processes including ribosome biogenesis, also functions as a nuclear PIP3 receptor (Ahn et al., 2005) . Upon NGF treatment, PIP3-bound NPM inhibits apoptosis through a direct interaction with caspase-activated DNase (CAD) that results in CAD inactivation. This antiapoptotic pathway is inhibited by PTEN and SHIP, which reduce the PIP3 pool. These data identify another AKT-independent pathway that is likely to be a physiological target of PTEN activity in the nucleus.
By using a series of PTEN mutants targeted to different cellular compartments of PTEN-null U251 glioblastoma cells, Liu et al. (2005) have recently started teasing out the possible physiological roles of nuclear PTEN. Their data strongly suggest that nuclear PTEN is not able to inhibit cell invasion, which thus seems to be a process controlled at the cytoplasmic level. Instead, nuclear-enforced PTEN can inhibit anchorageindependent growth and induce accumulation of the cells in G 1 . These findings suggest that these functions might be, at least in part, regulated at the nuclear level. One issue that will require further analysis is the fact that the authors found that nuclear localization of PTEN does not alter the phosphorylation levels of AKT (or its cytoplasmic target GSK3) and thus have proposed that PTEN mediates these nuclear tumor suppressive activities independent of AKT, through other pathways. This conclusion seems to be further supported by the fact that a constitutively active AKT mutant only partially rescues the phenotypes abrogated by nuclear PTEN. However, the nuclear/cytoplasmic ratio of AKT in these cells was not tested, so it is possible that a large cytoplasmic AKT pool might hide the effect of PTEN on nuclear AKT. Moreover, it was not shown whether the AKT mutant still localizes to the nucleus; thus, it is still possible that these pathways are regulated through the control of nuclear AKT activity.
In conclusion, a number of recent reports have reconciled years of anecdotic findings and brought solid evidence supporting the hypothesis that all the members of one of the most central signal transduction pathways, controlling multiple cellular functions involved in both homeostasis and transformation, live a double life as nuclear residents or commuters. While most preliminary data seem to support a clear separation between cytoplasmic and nuclear-controlled pathways and phenotypes, this area is likely to still reserve several surprises, which will keep it on the forefront of cancer research for quite some time.
